SCHEMBL17653201

SCHEMBL17653201

CNc1nc(CCC(C)C)nc2ccc(C=O)cc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AAK1 Q2M2I8 2/20 0.40
TRIM58 Q8NG06 1/20 0.34
KDM4E B2RXH2 2/20 0.33
MEN1 O00255 2/20 0.33
NPC1 O15118 2/20 0.33
ALDH1A1 P00352 2/20 0.33
POLB P06746 2/20 0.33
KMT2A Q03164 2/20 0.33
IP6K1 Q92551 1/20 0.32
MAPT P10636 1/20 0.32
HPGD P15428 1/20 0.32
RAB9A P51151 1/20 0.32
PTK2B Q14289 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
MELK Q14680 2/20 0.32
CCR4 P51679 2/20 0.31
HTR3A P46098 3/20 0.31
IDO1 P14902 1/20 0.30
TDO2 P48775 1/20 0.30
HRH4 Q9H3N8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17653415 0.88 AAK1 (0.40) AAK1TRIM58MELKCCR4HTR3A
SCHEMBL17653165 0.82 AAK1 (0.43) AAK1TRIM58KDM4EALDH1A1MAPT
SCHEMBL17653085 0.80 AAK1 (0.43) AAK1KDM4EMEN1NPC1ALDH1A1
SCHEMBL17653148 0.80 AAK1 (0.40) AAK1KDM4EMEN1NPC1ALDH1A1
SCHEMBL17653260 0.80 PDE10A (0.41) AAK1KDM4EMEN1NPC1ALDH1A1
SCHEMBL17653143 0.72 AAK1 (0.65) AAK1
SCHEMBL17653153 0.71 TUBB4A (0.44) AAK1KDM4EALDH1A1KMT2AIP6K1
SCHEMBL2882274 0.68 CYP1A2 (0.50) KDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL17653274 0.68 AAK1 (0.33) AAK1CCR4HRH4
SCHEMBL17653238 0.68 PDE10A (0.41) AAK1HTR3AHRH4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170239249-A1 QUINAZOLINE-BASED KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2017-08-24 US disclosed
US-20170239249-A1 QUINAZOLINE-BASED KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2017-08-24 US disclosed
US-20170239249-A1 QUINAZOLINE-BASED KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2017-08-24 US disclosed
EP-3200797-A1 QUINAZOLINE-BASED KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2017-08-09 EP disclosed
WO-2016053794-A1 QUINAZOLINE-BASED KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2016-04-07 WO disclosed
WO-2016053794-A1 QUINAZOLINE-BASED KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2016-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170239249-A1 QUINAZOLINE-BASED KINASE INHIBITORS AAK1, ULK1, NCK1 AAK1 1/4885TRIM58 760/4885KDM4E 1536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.